Literature DB >> 11545628

Hypothesis: can glucose-insulin-potassium regimen in combination with polyunsaturated fatty acids suppress lupus and other inflammatory conditions?

U N Das1.   

Abstract

In systemic lupus erythematosus, plasma concentrations of tumor necrosis factor alpha (TNF alpha) and other pro-inflammatory cytokines are elevated and those of transforming growth factor beta (TGF beta) are decreased. TNF alpha prevents lupus nephropathy whereas increased concentration of TGF beta causes glomerulosclerosis. Insulin inhibits TNF alpha and enhances TGF beta production, augments nitric oxide synthesis and blocks superoxide anion generation. Polyunsaturated fatty acids (PUFAs) also have actions similar to insulin. Hence, it is suggested that a combination of insulin (in the form of glucose-insulin-potassium) and PUFAs may be of benefit in lupus and other inflammatory conditions. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11545628     DOI: 10.1054/plef.2001.0297

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  4 in total

1.  A defect in the activities of Δ and Δ desaturases and pro-resolution bioactive lipids in the pathobiology of non-alcoholic fatty liver disease.

Authors:  Undurti N Das
Journal:  World J Diabetes       Date:  2011-11-15

2.  Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation.

Authors:  Undurti N Das
Journal:  J Inflamm Res       Date:  2010-12-02

3.  The significance of glucose, insulin and potassium for immunology and oncology: a new model of immunity.

Authors:  Albert F Hill; William J Polvino; Darcy B Wilson
Journal:  J Immune Based Ther Vaccines       Date:  2005-08-19

4.  Glucose-insulin-potassium infusion in sepsis and septic shock: no hard evidence yet.

Authors:  Iwan C C van der Horst; Jack J M Ligtenberg; Henk J G Bilo; Felix Zijlstra; Rijk O B Gans
Journal:  Crit Care       Date:  2002-10-09       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.